Consistent with the results from the plasma ALT, AST and ALP levels, MCD-fed mice treated with 2.4 mg metformin showed significantly suppressed development of MCD-induced liver steatosis by 75% (9.91±2.03 vs. 2.51±0.70%, P<0.001) (Fig. 2). The gene discussed is GPT; the disease is Hepatic steatosis.